Fig. 2: Tumor response. | Nature Communications

Fig. 2: Tumor response.

From: Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial

Fig. 2

a. Swimmer’s plot showing patterns of response in patients and the duration of response. b. Waterfall plot. All objective responses were confirmed by repeated imaging 4–6 weeks later. * Represents patients achieving complete response in target lesions, including three who only had lymph node target lesions. # One patient with HR-positive disease had no change in target lesions at the end of the treatment from baseline. HR, hormone receptor. Source data are provided as a Source Data file.

Back to article page